MaxCyte Revenue and Competitors
Estimated Revenue & Valuation
- MaxCyte's estimated annual revenue is currently $32.3M per year.
- MaxCyte received $1.7M in venture funding in December 2014.
- MaxCyte's estimated revenue per employee is $280,522
- MaxCyte's total funding is $31.3M.
- MaxCyte's current valuation is $793.5M. (January 2022}
- MaxCyte has 115 Employees.
- MaxCyte grew their employee count by 14% last year.
What Is MaxCyte?
MaxCyte is a global cell-based medicines and life sciences company applying its patented cell engineering technology to help patients with high unmet medical needs in a broad range of conditions. MaxCyte is developing novel CARMA therapies for its own pipeline. CARMA is MaxCyte's mRNA-based proprietary platform for autologous cell therapy. In addition, through its core business, the Company leverages its Flow Electroporation® Technology to enable its partners across the biopharmaceutical industry to advance the development of innovative medicines, particularly in cell therapy, including gene editing and immuno-oncology. The Company has placed its cutting-edge flow electroporation instruments worldwide, including with nine of the top 10 global biopharmaceutical companies, and has more than 55 partnered program licenses in cell therapy including more than 25 licensed for clinical use. With its robust delivery technology, MaxCyte helps its partners to unlock the full potential of their products. For more information, visit www.maxcyte.com.keywords:Biotechnology
Number of Employees
Employee Growth %
GAITHERSBURG, Md., Nov. 9, 2020 /PRNewswire/ -- MaxCyte, Inc., a global cell-based therapies and life sciences company, announces that its subsidiary CARMA Cell Therapies will share results of a detailed phenotypic and functional characterization of MCY-M11, its lead anti-mesothelin CAR-PBMC c ...
MaxCyte, Inc. ('MaxCyte' or the 'Company') MaxCyte Reports Final Results for the Year Ended 31 December 2020 Gaithersburg, Maryland -20 April 2021:MaxCyte (LSE: MXCT, MXCL, MXCN),a leading provider of cell-engineering platform technologies for next generation cell-based therapies, today annou ...
Nkarta to use MaxCyte’s Flow Electroporation® technology and ExPERT™ platform to accelerate the development of its oncology cell-therapy candidates SOUTH SAN FRANCISCO and GAITHERSBURG, Md., Oct. 28, 2021 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (Nasdaq: MXCT; LSE: MXCT, MXCN), a leading provider of ...
Gaithersburg, Maryland – 9 September 2019 – MaxCyte (LSE: MXCT, MXCS), the global cell-based therapies and life sciences company, ...
Investors in MaxCyte, Inc. (LON:MXCT) have tasted that bitter downside in the last year, as the share price dropped 49%. That contrasts poorly ...
MaxCyte, Inc. (AIM:MXCT) has a Piotroski F-Score of 2 at the time of writing. The F-Score may help discover companies with strengthening ...
|Company Name||Revenue||Number of Employees||Employee Growth||Total Funding|